Key result
Peak SBP during bevacizumab is linked to ~54% higher proteinuria risk per 10 mmHg increase.
Why the study?
Proteinuria and hypertension commonly occur during bevacizumab therapy, prompting investigation into the relationship between elevated blood pressure and the development of proteinuria in patients with female genital tract tumors.
Does elevated systolic blood pressure increase the risk of bevacizumab-induced proteinuria in patients with malignant tumors of the female genital tract?
Observational (n=79)
No
Does elevated systolic blood pressure increase the risk of bevacizumab-induced proteinuria in patients with malignant tumors of the female genital tract?
Effect estimate: OR 1.54 (95% CI 1.08-2.19)
p-value: p=0.016
Elevated systolic blood pressure (>154.5 mmHg) during bevacizumab therapy is a significant independent risk factor for developing proteinuria in patients with female genital tract malignancies.
May warrant closer SBP monitoring during bevacizumab; hypothesis-generating for trials on BP control to reduce proteinuria.
Proteinuria and hypertension are commonly observed during bevacizumab (BV) therapy. This study retrospectively investigated the relationship between elevated blood pressure during BV therapy and the development of proteinuria in patients with malignant tumors of the female genital tract treated with BV. Seventy-nine patients treated with BV at Shimane University Hospital between April 2015 and March 2020 were enrolled in the study. The highest values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during BV therapy were both significantly higher in the proteinuria group than the non-proteinuria group. Receiver operating characteristic curve analysis showed that the cutoff values for urinary protein expression were 154.5 mmHg for SBP and 100.5 mmHg for DBP, respectively. Stratified analysis showed that the highest SBP during BV treatment was significantly associated with the development of proteinuria regardless of stratification factors. Multivariate logistic regression analysis showed that the highest SBP was a significant risk factor for the development of proteinuria, independent of the positive urine protein dipstick test before starting BV therapy and the presence of combination treatment with renin-angiotensin system inhibitors. Furthermore, restricted cubic spline analysis indicated a significant dose-response association in the relationship between the elevation of highest SBP and the risk of proteinuria development. These results suggest the risk factor for the development of proteinuria in BV therapy is that SBP elevates above 154.5 mmHg during BV therapy in patients with malignant tumors of the female genital tract.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2022) conducted an observational in Malignant tumors of the female genital tract (n=79). Highest systolic blood pressure during bevacizumab therapy was evaluated on Development of grade ≥2 proteinuria (OR 1.54, 95% CI 1.08-2.19, p=0.016). The highest systolic blood pressure during bevacizumab therapy was a significant risk factor for the development of proteinuria in patients with female genital tract malignancies (OR 1.54 per 10 mmHg increase).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: